Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 2/20 | 0.37 |
| ▸ | ARG2 | P78540 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971344 | 0.94 | KCNA3 (0.38) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL8642327 | 0.92 | SPHK1 (0.40) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL2558770 | 0.88 | KCNA3 (0.41) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL5808106 | 0.80 | SIGMAR1 (0.50) | HRH3ACHESIGMAR1 | |
| SCHEMBL7291860 | 0.80 | GNAI3 (0.52) | SPHK1HRH3HRH2HRH1SIGMAR1 | |
| SCHEMBL1698806 | 0.77 | SPHK1 (0.57) | SPHK1GNAI3GNAO1GNAI1 | |
| SCHEMBL1099388 | 0.77 | KCNA3 (0.42) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL678406 | 0.76 | HRH3 (0.52) | HRH3HIF1A | |
| SCHEMBL2553857 | 0.76 | PDCD1 (0.40) | KCNA3HRH3HRH2HRH1PDCD1 | |
| SCHEMBL3951701 | 0.75 | HIF1A (0.38) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110295014-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022220-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100010227-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7560561-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-0877733-B1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | AMR TECHNOLOGY INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050272771-A1 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1362849-A2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2003-11-19 | — | — | EP | disclosed |
| US-6452011-B1 | NON-SEDATING ANTI-HISTAMINE H1 ANTAGONIST | ALBANY MOLECULAR RESEARCH, INC. | 2002-09-17 | — | — | US | disclosed |
| US-6448406-B1 | IMPROVED PROCESS FOR PREPARATION OF TERFENADINE CARBOXYLIC ACID METABOLITE AND CAREBASTINE DERIVATIVES; HISTAMINE H1 RECEPTOR BLOCKING AND CALCIUM ANTAGONISTS; RESPIRATORY, ALLERGIC, AND CARDIOVASCULAR DISEASE STATES | ALBANY MOLECULAR RESEARCH, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6201124-B1 | CONVERTING, WITH A PIPERIDINE COMPOUND, REGIOISOMERS UNDER NON-FRIEDEL-CRAFTS REACTION CONDITIONS | ALBANY MOLECULAR RESEARCH, INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0877733-A4 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0877733-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997022344-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295014-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | OR10J3, NR1H2, NR1H3 | KCNA3 872/4885SPHK1 3392/4885ARG1 1011/4885 |
| US-20050272771-A1 | Process for production of piperidine derivatives | HRH4, CBR1, CBR3 | KCNA3 656/4885SPHK1 3599/4885ARG1 300/4885 |
| US-20100010227-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | DDC, HPD, ALDH7A1 | KCNA3 987/4885SPHK1 2387/4885ARG1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.